New pill aims to smooth Parkinson's movement swings

NCT ID NCT05766813

Completed Disease control Sponsor: Intra-Cellular Therapies, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study tested a drug called lenrispodun in 79 people with Parkinson's disease who experience 'wearing off' symptoms and involuntary movements. Participants took the drug or a placebo once daily alongside their usual treatment. The goal was to see if lenrispodun could improve motor control and reduce troublesome symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lenrispodun (a drug taken as a tablet once daily)
What this could lead to: If it works, lenrispodun could help people with Parkinson's have more 'on' time with fewer movement problems, improving daily life.
What could go wrong: This is an early Phase 2 trial with only 79 people, so results may not apply widely. The drug may not work better than placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON DISEASE

Contacts and locations

Locations

Clinical Site

Phoenix, Arizona, 85013, United States
Clinical Site

Scottsdale, Arizona, 85251, United States
Clinical Site

Irvine, California, 92697, United States
Clinical Site

Loma Linda, California, 92354, United States
Clinical Site

Altamonte Springs, Florida, 32714, United States
Clinical Site

Boca Raton, Florida, 33486, United States
Clinical Site

Coral Springs, Florida, 33067, United States
Clinical Site

Doral, Florida, 33178, United States
Clinical Site

Hallandale, Florida, 33009, United States
Clinical Site

Maitland, Florida, 32751, United States
Clinical Site

Miami, Florida, 33136, United States
Clinical Site

Ocala, Florida, 34470, United States
Clinical Site

Orlando, Florida, 32804, United States
Clinical Site

Orlando, Florida, 32825, United States
Clinical Site

Port Orange, Florida, 32127, United States
Clinical Site

Tampa, Florida, 33612, United States
Clinical Site

Augusta, Georgia, 30912, United States
Clinical Site

Decatur, Georgia, 30030, United States
Clinical Site

Kansas City, Kansas, 66160, United States
Clinical Site

Farmington Hills, Michigan, 48334, United States
Clinical Site

Golden Valley, Minnesota, 55427, United States
Clinical Site

Albany, New York, 12208, United States
Clinical Site

Rock Hill, South Carolina, 29732, United States
Clinical Site

Franklin, Tennessee, 37067, United States
Clinical Site

Memphis, Tennessee, 38157, United States
Clinical Site

Austin, Texas, 78746, United States
Clinical Site

Dallas, Texas, 75243, United States
Clinical Site

Georgetown, Texas, 78628, United States
Clinical Site

Alexandria, Virginia, 22311, United States
Clinical Site

Falls Church, Virginia, 22042, United States
Clinical Site

Henrico, Virginia, 23233, United States
Clinical Site

Kirkland, Washington, 98034, United States
Clinical Site

Spokane, Washington, 99202, United States
Clinical Site

Crab Orchard, West Virginia, 25827, United States
Clinical Site

Milwaukee, Wisconsin, 53226, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.